Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW DRUGS

On September 28, 2022, the FDA approved bevacizumab-adcd (Vegzelma; Celltrion), a VEGF inhibitor and a biosimilar to bevacizumab (Avastin), for the treatment of metastatic colorectal cancer; recurrent or metastatic nonsquamous non–small-cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal-cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer. Bevacizumab-adcd is not indicated for the adjuvant treatment of colon cancer.

Bevacizumab-adcd is the fourth biosimilar to bevacizumab to be approved by the FDA. The approval was based on the totality of evidence showing no clinically meaningful differences in efficacy, safety, or pharmacokinetics between bevacizumab-adcd and the reference drug, including the results of a double-blind, randomized phase 3 clinical trial of 689 patients with metastatic or recurrent nonsquamous NSCLC.

In that study, the patients received 15 mg/kg of bevacizumab-adcd intravenously every 3 weeks for up to 6 cycles in the induction phase, followed by every 3 weeks until disease progression in the maintenance phase. The main end point was objective response at 21 weeks. The results showed that bevacizumab-adcd was highly similar to its reference drug in efficacy, safety, and pharmacokinetics.

The most common (>10%) adverse events with bevacizumab-adcd are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.